Improving the assessment of heart toxicity for all new drugs through translational regulatory science

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 5, 2014, Pages 501-508

  Johannesen, L ^a,b,c   Vicente, J ^b,d   Gray, R A ^b   Galeotti, L ^b   Loring, Z ^b   Garnett, C E ^a,e   Florian, J ^a   Ugander, M ^b,c   Stockbridge, N ^a   Strauss, D G ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e CERTARA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; NEW DRUG; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; ATRIOVENTRICULAR CONDUCTION; CARDIOTOXICITY; COMPUTER SIMULATION; DRUG CONTROL; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HEART ATRIOVENTRICULAR NODE; HEART BEAT; HEART DEPOLARIZATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HUMAN; IN VITRO STUDY; PLACEBO EFFECT; PR PROLONGATION; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; TORSADE DES POINTES;

CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS; TORSADES DE POINTES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84899409128     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.238     Document Type: Article

References (41)

1. Hamburg, M.A. Advancing regulatory science. Science 331, 987 (2011).
2. Availability of masked and de-identifed non-summary safety and efcacy data; request for comments. Fed. Reg. 78, 33421-33423 (2013).
3. Dessertenne, F. [Ventricular tachycardia with 2 variable opposing foci]. Arch. Mal. Coeur Vaiss. 59, 263-272 (1966).
4. Dessertenne, F., Gourgon, R., Coumel, P. & Fabiato, A. [Ventricular tachycardia and spike twisting]. Ann. Cardiol. Angeiol. (Paris). 20, 243-251 (1971).
5. US Food and Drug Administration. Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 〈http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm129357.pdf〉 (2005).
6. International Conference on Harmonisation. ICH Topic S7B The nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 〈http://www.ich.org/fleadmin/ Public-Web-Site/ICH-Products/Guidelines/Safety/S7B/Step4/S7B-Guideline. pdf〉 (2005).
7. Stockbridge, N., Morganroth, J., Shah, R.R. & Garnett, C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 36, 167-182 (2013).
8. Malik, M., Garnett, C.E. & Zhang, J. Thorough QT Studies: Questions and Quandaries. Drug Saf. 33, 1-14 (2010).
9. Trudeau, M.C., Warmke, J.W., Ganetzky, B. & Robertson, G.A. HERG, a human inward rectifer in the voltage-gated potassium channel family. Science 269, 92-95 (1995).
10. Acar, B., yi, G., Hnatkova, K. & Malik, M. Spatial, temporal and wavefront direction characteristics of 12-lead T-wave morphology. Med. Biol. Eng. Comput. 37, 574-584 (1999). (Pubitemid 29488393)
11. Couderc, J.P. et al. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition. Heart Rhythm 8, 1036-1043 (2011).
12. Graf, C. et al. Quantitative analysis of T-wave morphology increases confdence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. J. Clin. Pharmacol. 49, 1331-1342 (2009).
13. Antzelevitch, C. et al. Electrophysiological efects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004). (Pubitemid 39136212)
14. Zhang, S., Zhou, Z., Gong, Q., Makielski, J.C. & January, C.T. Mechanism of block and identifcation of the verapamil binding domain to HERG potassium channels. Circ. Res. 84, 989-998 (1999). (Pubitemid 29227678)
15. Wu, L. et al. Augmentation of late sodium current unmasks the proarrhythmic efects of amiodarone. Cardiovasc. Res. 77, 481-488 (2008). (Pubitemid 351197663)
16. Guo, D., Zhao, X., Wu, Y., Liu, T., Kowey, P.R. & yan, G.X. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. J. Cardiovasc. Electrophysiol. 18, 196-203 (2007). (Pubitemid 46130770)
17. January, C.T. & Riddle, J.M. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ. Res. 64, 977-990 (1989). (Pubitemid 19117651)
18. + channel and drug-induced prolongation of the QRS complex. Br. J. Pharmacol. 164, 260-273 (2011).
19. Redfern, W.S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003). (Pubitemid 36351620)
20. Grant, A.O. Cardiac ion channels. Circ. Arrhythm. Electrophysiol. 2, 185-194 (2009).
21. Johannesen, L. & Galeotti, L Automatic ECG quality scoring methodology: mimicking human annotators. Physiol. Meas. 33, 1479-1489 (2012).
22. Martínez, J.P., Almeida, R., Olmos, S., Rocha, A.P. & Laguna, P. A wavelet-based ECG delineator: evaluation on standard databases. IEEE Trans. Biomed. Eng. 51, 570-581 (2004). (Pubitemid 38375132)
23. Guldenring, D. et al. Transformation of the Mason-Likar 12-lead electrocardiogram to the Frank vectorcardiogram. Conf. Proc. IEEE Eng. Med Biol. Soc. 2012, 677-680 (2012).
24. Fridericia, LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica 54, 17-50 (1920).
25. Malik, M., Zhang, J., Johannesen, L., Hnatkova, K. & Garnett, C. Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability. Heart Rhythm 8, 1777-1785 (2011).
26. Gintant, G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol. Ther. 129, 109-119 (2011).
27. Narimatsu, A. & Taira, N. Efects of atrio-ventricular conduction of calcium-antagonistic coronary vasodilators, local anaesthetics and quinidine injected into the posterior and the anterior septal artery of the atrio-ventricular node preparation of the dog. Naunyn Schmiedebergs Arch. Pharmacol. 294, 169-177 (1976).
28. O'Hara, T., Virág, L, Varró, A. & Rudy, Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput. Biol. 7, e1002061 (2011).
29. Oosterom, A.v. & Oostendorp, T.F. ECGSIM: an interactive tool for studying the genesis of QRST waveforms. Heart 90, 165-168 (2004). (Pubitemid 38147151)
30. Mirams, G.R. et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61 (2011).
31. van Oosterom, A. Genesis of the T wave as based on an equivalent surface source model. J. Electrocardiol. 34(suppl.), 217-227 (2001). (Pubitemid 34083926)
32. van Dam, P.M., Oostendorp, TF., Linnenbank, A.C. & van Oosterom, A. Noninvasive imaging of cardiac activation and recovery. Ann. Biomed. Eng. 37, 1739-1756 (2009).
33. Antzelevitch, C. & Fish, J. Electrical heterogeneity within the ventricular wall. Basic Res. Cardiol. 96, 517-527 (2001). (Pubitemid 33121024)
34. Bigger, J.T. Jr & Mandel, W.J. Efect of lidocaine on the electrophysiological properties of ventricular muscle and purkinje fbers. J. Clin. Invest. 49, 63-77 (1970).
35. Kramer, J. et al. MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 3, 2100 (2013).
36. Po, S.S., Wang, D.W., yang, I.C. Johnson, J.P. Jr, Nie, L. & Bennett, P.B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J. Cardiovasc. Pharmacol. 33, 181-185 (1999). (Pubitemid 29066657)
37. Roden, D.M., Woosley, R.L. & Primm, R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart J. 111, 1088-1093 (1986). (Pubitemid 16085013)
38. Lu, Z. et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci. Transl. Med. 4, 131ra50 (2012).
39. Dombrowski, C. FDA seeks alternatives to QT interval for assessing risk of torsade de pointes. In: The Pink Sheet. 〈http://www.elsevierbi.com/ publications/the-pink-sheet/75/26/fda-seeks-alternatives-to-qt-interval-for- assessing-risk-of-torsade-de-pointes〉 (2013).
40. Chen, J. et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144, 1450-1455.e2 (2013).
41. Malmivuo, J. & Plonsey, R. The heart. In: Bioelectromagnetism- Principles and Applications of Bioelectric and Biomagnetic Fields. (Oxford University Press, New york, 1995).